Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurofibromatosis 1.

Timothy M Lynch1, David H Gutmann

  • 1Department of Neurology, Washington University School of Medicine, Neurofibromatosis Program, St. Louis Children's Hospital, St. Louis, MO, USA.

Neurologic Clinics
|November 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nested pediatric low-grade glioma cerebral organoid avatars reveal glutamatergic neuron stromal growth dependency.

Genes & development·2026
Same author

Differences in Optic Pathway Glioma Prevalence Among Children with Neurofibromatosis Type 1.

The Journal of pediatrics·2026
Same author

Central Precocious Puberty and Optic Pathway Glioma in Children with Neurofibromatosis 1: Associations with Tumor Location, Vision, and Treatment.

The Journal of pediatrics·2026
Same author

Nested ecosystems theory for conceptualizing brain tumors.

Disease models & mechanisms·2026
Same author

Time trends in the male to female ratio for autism incidence: population based, prospectively collected, birth cohort study.

BMJ (Clinical research ed.)·2026
Same author

Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.

Neuro-oncology advances·2026
Same journal

Sports Neurology.

Neurologic clinics·2026
Same journal

Sports-Related Peripheral Nerve Injuries.

Neurologic clinics·2026
Same journal

Active Rehabilitation and Return to Play in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Autonomic Assessment and Management in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Management of Vestibular Symptoms in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Neuropsychological Assessment in Sport-Related Concussion: Evidence, Controversies, and Clinical Applications.

Neurologic clinics·2026
See all related articles

Neurofibromatosis 1 (NF1) is a common genetic disorder causing tumors and other health issues. Targeting the RAS signaling pathway, affected by the NF1 gene, may offer new therapeutic strategies for NF1 patients.

Area of Science:

  • Genetics
  • Oncology
  • Neurology

Background:

  • Neurofibromatosis 1 (NF1) is a prevalent genetic disorder impacting the nervous system.
  • Individuals with NF1 have an increased risk of developing various tumors, including neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs).
  • NF1 is also associated with neurological complications like learning disabilities, seizures, and optic pathway gliomas.

Purpose of the Study:

  • To explore the genetic underpinnings of Neurofibromatosis 1.
  • To identify potential therapeutic targets for NF1-associated conditions.
  • To investigate the role of the NF1 gene in tumor development and signaling pathways.

Main Methods:

  • Review of genetic and molecular mechanisms underlying NF1.
  • Analysis of the function of the NF1 gene product, neurofibromin.

Related Experiment Videos

  • Exploration of the RAS signaling pathway in the context of NF1.

    • Main Results:

    • The NF1 gene encodes neurofibromin, a key negative regulator of the RAS signaling pathway.
    • Dysregulation of the RAS pathway is implicated in the pathogenesis of NF1-associated tumors.
    • The function of neurofibromin highlights the RAS pathway as a potential therapeutic target.

    Conclusions:

    • Targeting the RAS signaling pathway presents a promising therapeutic avenue for Neurofibromatosis 1.
    • Understanding neurofibromin's role is crucial for developing effective NF1 treatments.
    • Further research into RAS pathway inhibitors could benefit NF1 patients.